S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Forecast, Price & News

$2.23
+0.04 (+1.83%)
(As of 09/21/2023)
Compare
Today's Range
$2.19
$2.24
50-Day Range
$2.17
$2.23
52-Week Range
$1.29
$3.65
Volume
4.76 million shs
Average Volume
724,253 shs
Market Capitalization
$127.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.58

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
60.3% Upside
$3.58 Price Target
Short Interest
Healthy
6.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
0.85mentions of Paratek Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$313,161 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

793rd out of 971 stocks

Biotechnology Industry

16th out of 25 stocks


PRTK stock logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

PRTK Price History

PRTK Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
PRTK Paratek Pharmaceuticals, Inc.
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings
8/03/2023
Today
10/01/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
268
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$3.58
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.15
Forecasted Upside/Downside
+60.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-63,570,000.00
Pretax Margin
-35.35%

Debt

Sales & Book Value

Annual Sales
$160.27 million
Book Value
($3.08) per share

Miscellaneous

Free Float
52,736,000
Market Cap
$127.82 million
Optionable
Optionable
Beta
1.70

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Michael F. Bigham CPAMr. Michael F. Bigham CPA (Age 65)
    CPA, M.B.A., MBA, Exec. Chairman
    Comp: $954.39k
  • Dr. Evan Loh FACC (Age 64)
    FAHA, M.D., CEO & Director
    Comp: $1.14M
  • Mr. Adam WoodrowMr. Adam Woodrow (Age 56)
    Pres & Chief Commercial Officer
    Comp: $763.51k
  • Ms. Sarah Higgins (Age 48)
    VP of Fin., Controller & Principal Accounting Officer
  • Mr. William M. HaskelMr. William M. Haskel (Age 61)
    Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.
  • Mr. Jonathan Light
    Deputy Gen. Counsel & Chief Compliance Officer
  • Ms. Karen McGrath
    Chief People Officer
  • Mr. Randall B. BrennerMr. Randall B. Brenner (Age 50)
    Chief Devel. & Regulatory Officer













PRTK Stock - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares.
View PRTK analyst ratings
or view top-rated stocks.

What is Paratek Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $2.15 to $5.00. On average, they predict the company's stock price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How have PRTK shares performed in 2023?

Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of 2023. Since then, PRTK shares have increased by 19.3% and is now trading at $2.23.
View the best growth stocks for 2023 here
.

When is Paratek Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRTK earnings forecast
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Thursday, August, 3rd. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. The specialty pharmaceutical company earned $39.99 million during the quarter, compared to the consensus estimate of $34.63 million.

What ETF holds Paratek Pharmaceuticals' stock ?

AltShares Event-Driven ET holds 17,764 shares of PRTK stock, representing 1.36% of its portfolio.

What other stocks do shareholders of Paratek Pharmaceuticals own?
What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $2.23.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $127.82 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

The company employs 268 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -